Docoh
Loading...

ABUS Arbutus Biopharma

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM



At the Meeting, the shareholders voted and: (1) elected each of the Company’s nominees for director; (2) approved the Plan Amendment; (3) approved, by non-binding advisory vote, the compensation of the Company’s named executive officers; (4) approved, by non-binding advisory vote, “1 year” as the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers; and (5) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s shareholders at the Meeting.




Proposal 1.To elect the eight director nominees named in the Proxy Statement/Circular each to serve until the 2022 Annual General Meeting of Shareholders or until his qualified successor has been duly elected or appointed.


NomineeVotes
For
Votes
Withheld
Broker
Non-Votes
Frank Torti, M.D.36,995,9541,124,46220,096,095
William H. Collier36,797,7691,322,64720,096,095
Daniel Burgess34,772,8993,347,51720,096,095
Richard C. Henriques36,644,6251,475,79120,096,095
Keith Manchester, M.D.34,791,4483,328,96820,096,095
Eric Venker, M.D., Pharm D.37,107,2541,013,16220,096,095
James Meyers34,700,9733,419,44320,096,095
Andrew Cheng, M.D., Ph.D.37,104,4411,015,97520,096,095











Proposal 2.To approve an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,000,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,000,000 common shares:


Votes
For
Votes WithheldVotes
Abstained
Broker
Non-Votes
34,217,0103,447,396456,03720,096,068








Proposal 3.To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers:


Votes
For
Votes
Withheld
Votes
Abstained
Broker
Non-Votes
34,997,4092,754,917368,08920,096,096








Proposal 4.To approve, by a non-binding advisory vote, the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers:


1 Year2 Years3 YearsAbstain
35,659,0871,472,883714,128274,212





The Company has determined, in light of and consistent with the advisory vote of the Company’s stockholders as to the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, to include a stockholder advisory vote on the compensation of the Company’s named executive officers in its annual meeting proxy materials once every year until the next advisory vote on the frequency of stockholder votes on the compensation of the Company’s named executive officers.




Proposal 5.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021:


Votes
For
Votes
Withheld
Votes
Abstained
Broker
Non-Votes
56,113,2411,430,271672,999